Table 1. Baseline characteristics of the two treatment arms and comparison of HIV-infected to HIV-uninfected controls.
| cART | cART+ | Control | p-value cART vs. cART+ | p-value HIV+ vs. HIV- | |
|---|---|---|---|---|---|
| Enrollment, sample size | 30 | 32 | 29 | ||
| Age, median (range) years | 27 (18–47) | 28 (20–49) | 35 (22–46) | 0.137 1 | 0.007 1 |
| Gender, n (%) male | 28 (93) | 30 (94) | 16 (55) | 0.999 2 | <0.001 2 |
| Education, mean (SD) years | 16 (3.4) | 17 (3.6) | 13 (5.4) | 0.849 3 | <0.001 3 |
| Estimated duration of HIV [Number of days, mean (SD)] | 18 (6.8) | 17 (7.8) | —- | 0.546 3 | n/a |
| Fiebig stage [n (%) at F1/F2 vs. F3/F4/F5] | 14 (47%) | 13 (41%) | —- | 0.842 2 | n/a |
| Baseline CD4 T-lymphocyte count, median (IQR) | 369 (277) | 391 (218) | — | 0.706 1 | n/a |
| Baseline Plasma viral load, mean log10 (SD) | 5.5 (1.11) | 5.6 (1.33) | — | 0.838 3 | |
| Baseline CSF viral load, mean log10 (SD) | 2.1 (1.89) | 3.3 (1.57) | 0.059 3 |
1.Wilcoxon Rank Sum test
2. Fisher’s Exact test
3. Student t-test.